Recurrent Small Cell Lung Cancer Clinical Trial
Official title:
A Pilot Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Small Cell Lung Carcinoma (SCLC)
This pilot clinical trial studies CPI-613 (6,8-bis[benzylthio]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the growth of tumor cells and may be an effective treatment for small cell lung cancer.
PRIMARY OBJECTIVES:
I. To evaluate the safety and anti-cancer activities in patients with relapsed or refractory
small cell lung cancer (SCLC) who have failed 1 or 2 lines of chemotherapy.
OUTLINE:
Patients receive CPI-613 intravenously (IV) over 2 hours on days 1 and 4 of weeks 1-3.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 2 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01935336 -
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Terminated |
NCT04610658 -
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
|
Phase 1 | |
Completed |
NCT00773955 -
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00528645 -
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00028535 -
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03732846 -
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00828139 -
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00086827 -
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00052949 -
Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT01325753 -
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
|
N/A | |
Not yet recruiting |
NCT05162196 -
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01155258 -
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT00088933 -
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT00020202 -
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01901653 -
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00182689 -
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01457469 -
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
|
Phase 1 | |
Completed |
NCT00098956 -
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT01803269 -
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
|
Phase 2 |